The Dako PD-L1 IHC 22C3 pharmDx Pathology Training Program
The PD-L1/PD-1 pathway is a new target for novel treatments. Get educated on how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx.
The Dako PD-L1 IHC 22C3 pharmDx Pathology Training Program uses in-depth content, engaging activities, and comprehensive cases to help you confidently:
- Understand the core principles of PD-L1 pathology
- Learn the process for evaluating stained images for PD-L1 expression
- Recognize confounding considerations that affect PD-L1 scoring
- Score images for PD-L1 expression across a variety of patient samples
Get started
For in vitro diagnostic use.
PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue using EnVision FLEX visualization system on Autostainer Link 48.
PD-L1 protein expression is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining. The specimen should be considered PD-L1 positive if TPS ≥ 50% of the viable tumor cells exhibit membrane staining at any intensity.
PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA® (pembrolizumab).
3385 2015DEC01